US3906086A - Timed-release aspirin - Google Patents

Timed-release aspirin Download PDF

Info

Publication number
US3906086A
US3906086A US43541874A US3906086A US 3906086 A US3906086 A US 3906086A US 43541874 A US43541874 A US 43541874A US 3906086 A US3906086 A US 3906086A
Authority
US
Grant status
Grant
Patent type
Prior art keywords
aspirin
particles
granules
weight
timed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
Inventor
Michael G Guy
Richard G Powers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BOOTS PHARMACEUTICALS Inc A LA CORP
Hitachi Ltd
Original Assignee
Richard G Powers
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Grant date

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/60Salicylic acid; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61JCONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/10Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5036Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose

Abstract

Timed-release aspirin is made by coating particles of aspirin prior to tabletting with a coating solution containing cellulose acetate phthalate. The tablet so produced remains substantially in tact while in the stomach and dissolves at a slow, controlled rate in the intestinal tract. Aspirin tablets providing both immediate pain relief and timed-release are produced by pressing separate layers of aspirin particles coated in this manner and ordinary uncoated aspirin into a double-layered tablet.

Description

United States Patent Guy et al. Sept. 16, 1975 [54] TIMED-RELEASE ASPIRIN 2,953,497 9/1960 Press 424/35 1 3,112,220 .11 1963 H t 117 100 [75] Inventors: Michael G. Guy, Ferdonia; Richard 3247 066 4, a :22 t 422/35 Saukvillc, both of 3,325,365 6/1967 Hotko ct 211.... 424 33 3,400,185 9/1968 Kohnlc et al. 424/35 Assignees: Richard G. Powers, Saukville;

Michael G. Guy, Ferdonia; James F. Stern; Robert M. Stern, both of Milwaukee, all of Wis,

22 Filed: Jan. 22, 1974 [21] Appl. No.: 435,418

Related US. Application Data [63] Continuation of Ser. No. 163,739, July 19, 1971,

abandoned.

[52] US. Cl. 424/20; 117/652; 117/66; 117/100; 264/117; 264/122; 264/123; 264/131; 264/134; 424/19; 424/35; 424/230 [51] Int. Cl. A61J 3/10; A61K 27/12 [58] Field of Search 424/20, 35, 230; 117/100, 117/652, 66;264/117,122123,131,134

[56] References Cited UNlTED STATES PATENTS 2,196,768 4/1940 Hiatt 424/35 Primary ExaminerShep K. Rose [57] ABSTRACT Timed-release aspirin is made by coating particles of aspirin prior to tabletting with a coating solution containing cellulose acetate phthalate. The tablet so produced remains substantially in tact while in the stomach and dissolves at a slow, controlled rate in the intestinal tract. Aspirin tablets providing both immediate pain relief and timed-release are produced by pressing separate layers of aspirin particles coated in this manner and ordinary uncoated aspirin into a double-layered tablet.

7 Claims, 2 Drawing Figures TllMlElD-RELIEASIE ASPIRIN BACKGROUND OF THE INVENTION This is a Continuation of application Ser. No. 163,739, filed July 19, 1971 and now abandoned.

This invention relates to parrnaceutical preparations, and more particularly to pharmaceutical preparations having timed-release characteristics and a method for making same.

The maximum time of efiectiveness in many pharmaceutical preparations, particularly those containing aspirin as the active analgesic agent, is only a few hours because of biological decomposition of the medication in the body. Consequently, repeated dosages must be taken at frequent intervals to obtain long term pain relief. Furthermore, aspirin usually dissolves readily in the gastric juices of the stomach and the total dosage is immediately fed into the blood stream. The level of the aspirin in the blood stream constantly decreases because of the biological decomposition, so there is little or no pain relief at the end of the period between dosages. As a result, the pair relief fluctuates between dosages corresponding to the peaks and valleys in the level of aspirin in the blood.

Many attempts have been made to develop timedrelease pharmaceutical preparations which provide a more constant level of aspirin in the blood over several hours. Generally, three different approaches have been employed to obtain a timed release. In one approach, employing digestion as the release mechanism, the aspirin is either coated or entrapped in a substance which is slowly digested or dispersed into the intestinal tract. The rate of availability of the aspirin is a function of the rate of digestion of the dispersible material. Therefore, the release rate, and thus the analgesic effectiveness of the aspirin, varies from patient to patient depending upon the ability of the patient to digest the material.

In another approach, such as disclosed in US. Pat. No. 3,247,066, the aspirin is dispersed in a watersoluble colloid and then coated with a rupturable plastic, non-digestable material which is permeable to the diffusion of water. After ingestion and upon enteringthe gastrointestinal tract, water in the body fluids diffuses through the coating and causes the colloid to swell. The coating is ruptured by the swelling colloid and the total content of aspirin is released. Although there is substantially less variation in the rate of release from patient to patient, substantially all of the aspirin is released at once resulting in an initially high blood level content which decreases rapidly with time. Also, the additional ingredients and processing steps to disperse the aspirin in the colloid and provide the coating substantially increases the cost of the product.

in another approach commonly referred to as microencapsulation, such as disclosed in U.S. Pat. Nos. 3,488,418, 3,341,416 and 3,155,590, particles of aspirin are first dispersed in a hot solution containing ethyl cellulose and a phase-separation inducing agent, such as butyl rubber or polyethylene. Upon cooling the aspirin particles become coated with ethyl cellulose. The coat-ed particles are then admixed with tabletting excipients and formed into dosage-sized tablets. When ingested, the tablets disintegrate rapidly and the individual particles of encapsulated aspirin are dispersed in the stomach. The gastric juices slowly diffuse through the encapsulant walls, dissolve the aspirin, and the dissolved aspirin slowly diffuses or leaches out through the encapsulant walls into the body. Although the resultant blood level content remains more constant, the aspirin is diffused into the body rapidly enough so there is an initially high blood level content which decreases quite rapidly within a few hours, apparently because of the large surface area contact between the body fluids and the small encapsulated particles. Also, the cost of the additional ingredients and multiple processing steps add to the overall cost of the product.

U.S. Pat. No. 3,1 15,441 discloses another encapsulation method wherein particles of aspirin are first given a quick thin coating of a film-forming material and a non-toxic, hydrophobic material and are then coated with successive coatings of an organic solvent-resistant material. The coated particles are mixed with uncoated aspirin and this mixture is then formed into a tablet with the coated tablets being entrapped in a matrix of the uncoated aspirin. Tablets made accordidng to this method have the advantage of providing immediate relief because the matrix material (which comprises the initial dosage) dissolves immediately upon ingestion. However, as with the other preparations employing the diffusion technique discussed above, the tablet rapidly disintegrates in the stomach and there is a relatively rapid release of the aspirin. Also, the several coating steps of the process add to the overall cost of the product.

, SUMMARY OF THE INVENTION The primary object of this invention is to provide a simple, inexpensive method for making a timed-release pharmaceutical preparation containing aspirin as the active therapeutic agent which produces an improved blood level profile of the aspirin for prolonged durations.

Another object of this invention is to provide such a product which is also capable of providing immediate medication upon ingestion.

It has been found that aspirin tablets providing an improved blood level profile can be prepared by simply applying a film of a non-aqueous solution of cellulose acetate phthalate over either individual particles of aspirin before tabletting or over the outside of tablets formed from untreated aspirin particles, which upon drying forms a coating of cellulose acetate. When individual particles of aspirin are used, they are first coated with the solution, preferably during granulation, then, after drying, are formed into dosage-size tablets. The cellulose acetate phthalate is substantially insoluble in the acidic gastric juices of the stomach and the tablet remains in tact until it reaches the intestinal tract rather than disintegrating in the stomach and dispersing the individual aspirin particles. From in vitro and in vivo tests, it has been found that the aspirin is released in the intestinal tract at a slow, controlled rate as the cellulose acetate phthalate coating is eroded away by the alkaline intestinal fluids. The dissolution of the tablet as the coating erodes away appears to be somewhat analogous to that of a melting ice cube. Hence, the danger of damage from small particles lodging in a stomach or intesti nal urevise associated with prior art timed-release phar maceutical preparations is eliminated.

Because of the slow, controlled release rate of aspirin tablets prepared in accordance with this invention, a higher initial dosage can be taken without producing a high peak in the blood level content with potential toxicity and/or harmful side effects. Furthermore, by taking smaller dosages at regular intervals following the initial dose, the aspirin content in the blood can be maintained at a relatively constant pain relief level for periods of 24 hours or longer. This is a significant improvement over presently available timed-rclease aspirin which produce a blood level profile with substantial peaks and valleys between dosages and are ineffective within a few hours after ingestion.

In order to obtain both immediate and prolonged pain relief, a separate layer of uncoated aspirin particles can be tabletted with a layer of aspirin particles coated with cellulose acetate phthalate. The layer of uncoated particles dissolves in the stomach while the layer of coated particles remains in tact until reaching the intestinal tract where it dissolves at a slow, controlled rate.

The process of this invention basically is the same as that for making ordinary aspirin tablets with the simple additional step of applying the coating solution to the aspirin particles before tabletting or to the outside of the tablet after it is formed. Hence, the cost for incorporating a timed-release characteristic is drastically reduced from that of prior art techniques requiring multiple and complex coating and/or matrixing steps, as well as costly coating ingredients. Also, all the ingredients of the cellulose acetate phthalate coating solution remaining after drying are soluble in the body and are well known to be safe for human consumption. It has been found that timed-release aspirin prepared in accordance with this invention has excellent stability against hydrolysis and other chemical reactions. Hence, the aspirin has long term shelf life capabilities; a capability which many available timed-release preparations do not possess.

DESCRIPTION OF THE DRAWINGS FIG. 1 is a graphical illustration of the results of the tests described in Example IV showing blood level profiles for aspirin made in accordance with this invention and a commercially available timed-release aspirin.

FIG. 2 is a graphical illustration of the results of the test described in Example VI showing the blood level profile when successive doses of timed-release aspirin produced in accordance with this invention are taken.

DESCRIPTION OF THE PREFERRED EMBODIMENT The coating solution used in this invention is made by dissolving cellulose acetate phthalate in a suitable nonaqueous, pharmaceutically acceptable (i.e., safe for human consumption) solvent. A wide variety of polar and non-polar organic solvents which are safe for human use and are capable of dissolving cellulose acctate phthalate are well known. Representative examples of such solvents include acetone, methyl ethyl ketone, methanol, ethanol, isopropanol, methylene chloride, ethylene dichloride, chloroform, and mixtures of these solvents. Presently the preferred solvent is a mix ture of acetone and methylene chloride, It has been found that coating solutions containing concentrations of cellulose acetate phthalate over relatively broad ranges can be used to obtain the improved timedrelease characteristics of this invention. For example, coating solutions containing as little as 0.125% cellulose acetate phthalate by weight have been found sufficient to impart a slow timed-release characteristic to aspirin. Because of the cost of cellulose acetate phthalate, an upper practical limit of the cellulose acetate phthalate concentration in the coating solution generally is about 20% by weight, although higher concentrations can be used if desired. The preferred concentration of cellulose acetate phthalate in the coating solution is in the range of about 5 to about 18 percent by weight with a concentration of about 15 percent by weight being the most preferred. The coating solution can also include conventional pharmaceutically acceptable (i.e., safe for human consumption) plasticizers, such as diethylphthalate, to improve the flexibility of the resultant tablets and minimize their tendency to break up during handling. Representative examples of other conventional plasticizers include those disclosed in the Hotko et al. US. Pat. No. 3,325,365 and the Gaunt US. Pat. No. 3,449,489. That is, esters of carboxylic acids, such as lower alkyl citrates, e.g., triethyl citrate and the like; acetyltributyl citrate; aeetyltriethyl citrate; other phthalate esters, such as dimethylphthalate; and other esters, such as benzyl benzoate.

The coating solution can be applied either to the partieles of aspirin before tabletting or to the outer surface of tablets formed from ordinary aspirin containing conventional tabletting excipients, such as starch. When applied to preformed tablets of uncoated aspirin, the coating solution is applied directly to the outer surface of the tablet without any previous coatings, such as gelatin, natural gums, calcium sulfate or the like, typically used in enteric coating processes.

The coating solution is applied to the aspirin particles or aspirin tablet in any convenient manner capable of providing a continuous thin film of the cellulose acetate phthalate solution over the particles or tablet. When coating aspirin particles, the coating solution can be conveniently applied by spraying, dipping, ladling while the particles are being tumbled in a conventional apparatus or the like. Presently, the preferred method of coating the aspirin particles is to granulate standard size aspirin in the presence of a sufficient amount of the coating solution to completely coat each of the individual particles with a thin film of the solution. Since ordinary aspirin is typically granulated before being formed into a tablet, application of the coating solution in this manner does not require a separate coating step and production costs are minimized. In order to obtain the best results, the coating solution is slowly introduced into the granulating equipment while the aspirin particles are being granulated, e.g., over a l to 5 minute period, and the granulation is continued for a few additional minutes after all the coating solution has been added, e.g., 3 to 10 minutes, to insure each particle is coated with a thin film of the solution.

Although the release time can be varied by varying the size of the aspirin particles, it does not appear that particle size of the aspirin before and after granulation is particularly critical for obtaining the improved timed-release characteristics. Of course, particle sizes which are convenient for granulating and forming the granules into dosagesize tablets should be used. For example, it has been found that standard mesh U.S.P. aspirin granulated into 20 mesh or larger granules works very satisfactorily. The release time is increased as the size of the aspirin particles is reduced because of the larger total surface area of coating per unit mass which must be eroded away by the intestinal fluids. The thickness of the resulting coating on the aspirin particles is primarily dependent upon the quantity of coating solution used during granulation, the concentration of cellulose acetate phthalate in the coating solution and the total granulating time. The thickness of the coating is generally increased, thus the release time increased, as these variables are increased. Therefore, these variables are adjusted to obtain a coating thick ness which produces the desired timed-release characteristics. Typically, the amount of cellulose acetate phthalate applied to the aspirin particles, after removal of the solvent by drying, will be in the range of about 0.5 to about 5.0% by weight based on the total weight of the coated granules.

After applying the coating solution, the aspirin granules are dried. During the drying step, the granules are subjected to a temperature sufficient to evaporate substantially all of the solvent, thereby leaving a continuous coating of cellulose acetate phthalate over the granules. Following the drying step, the coated granules are treated in a conventional manner for forming a tablet, e.g., ground into convenient size for tabletting, mixed to homogenize the batch and formed into appropriate dosage-size tablets, (e.g., grains) in a tablet press.

When the coating solution is applied to preformed tablets of untreated aspirin, the coating solution can be applied by spraying, dipping, ladling onto the tablets while they are being tumbled in a conventional apparatus and the like. From test results, it appears that the cellulose acetate phthalate is at least partially absorbed into the tablet and protectively coats the individual par ticles thereof. It has been found that the release pattern of the tablets so treated is substantially the same as that for tablet formed from coated aspirin particles. Where a slower release rate is desired, two or more coatings can be applied, with an intermediate drying step, to obtain a thicker resultant coating. Since coating tablets in this manner does require a separate coating step, with the attendant additional time and cost therefor, this method has less practical advantages from a production cost standpoint than granulating the aspirin particles in the presence of the coating solution before tabletting.

For some purposes, it may be desirable for an aspirin tablet to provide both immediate pain relief and sustained pain relief. This capability can be provided by forming a double-layered tablet, one layer being formed from aspirin particles containing conventional tabletting excipients and the other layer being formed from particles of aspirin coated in accordance with this invention. The separate layers of particles are introduced into a conventional two layer tablet press where they are pressed into a single double-layered tablet. The quantity of aspirin in each layer is varied depending upon the desired dosage for each type of pain relief. For example, a double-layered tablet having a total dosage of 10 grains can be produced with 6 grains being coated, time-release aspirin and 4 grains being ordinary aspirin. When a double-layered tablet pre pared in this manner is ingested, the layer of ordinary, uncoated aspirin dissolves immediately in the stomach to provide immediate relief. The layer of coated aspirin remains in tact while in the stomach and dissolves at a slow, controlled rate in the intestinal tract to maintain a level of pain relief for a sustained period of time. When preformed tablets of untreated aspirin are coated with the coating solution in accordance with one embodiment of this invention, it cannot be made into a double-layer tablet because of the inability of the layer of uncoated aspirin to adequately adhere to the coated tablet. Therefore, aspirin tablets should be coated previously to tabletting and pressed into a tablet along with the ordinary aspirin when a double-layered tablet is to be made.

EXAMPLE I A representative coating solution is made according to the following formulation:

The cellulose acetate phthalate is first added to the acetone and mixed to obtain complete dissolution. The diethylphthalate is added to the solution while mixing and the methylene chloride is then added to obtain the coating solution.

65kg of mesh aspirin U.S.P. are placed in a Hobart mixer and, while mixing, two gallons of the above coating solution are introduced into the mixer over a period of 2 minutes. After addition of the coating solution, mixing is continued for an additional 4 minutes (6 minutes total mixing) to insure that the individual particles of the aspirin and'the resultant granules are completely coated with a thin film of the solution. The thus-coated aspirin granules are transferred to paper-lined oven trays, dried in ambient air for one hour and then subsequently dried in an oven at F for H2 hours. The dried granules, containing approximately 0.76 to 0.91% cellulose acetate phthalate by weight, are then removed from the oven and are allowed to cool at room temperature for 30 minutes. The cooled granules are then introduced into a Fitzmill grinder in which they are ground into a smaller size and forced through a 20 mesh screen. The granules are mixed in a Hobart mixer for about 2 minutes to homogenize the batch. The total weight of the granules is approximately 65.8 kg. The coated aspirin granules are then pressed into dosagesized tablets (e.g., 10 grains) in a conventional tabletting press.

EXAMPLE ll A double-layer aspirin tablet having one layer of timed-release aspirin and one layer of standard aspirin are pressed in a conventional two layer press. The timed-release layer consists of 6 grains of aspirin granules prepared in accordance with the procedure outlined in Example I and the other layer consists of 4 grains of standard 80 mesh aspirin admixed with starch as a tabletting excipient, the amount of starch being approximately 10% by weight of the admixture.

EXAMPLE III A double-layered tablet prepared in accordance with the procedure outlined in Example II was subjected to standard U.S.P. in vitro disintegration tests using simulated gastric juice and intestinal fluid. The layer of standard aspirin was completely dissolved in the gastric juice within 45 seconds and approximately 5.6 weight percent of the timed-release layer dissolved in the gastric juice after one hour. The dissolution of the timed- TABLE I Cumulative WW7! Timed- Release Layer Dissolved Total Time in Intestinal Fluid (after 1 hour in gastric juice).

Hours From these test results it can be seen that there is minimal dissolution of the timed-release layer in the simulated gastric juice while there is a complete dissolution thereof in the simulated intestinal fluid at a very slow rate.

Aspirin tablets containing about starch by weight have been coated with the coating solution described in Example II by ladling the solution on while the tablets were being tumbled. In vitro tests of tablets coated in this manner produced results substantially the same as those described above for tablets formed from coated aspirin particles.

EXAMPLE IV In vivo tests were performed with a 10 grain aspirin tablet prepared in accordance with the procedure outlined in Example I (designated A below), a doublelayered combination l0 grain tablet prepared in accordance with the procedure outlined in Example II (designated B below) and a commercially available timedrelease 10 grain aspirin tablet prepared by an ethyl cellulose microencapsulation procedure (designated C below) to evaluate their biological availability. The tablets were ingested on different days by a 42 year old male, 5'8" tall and weighing 168 pounds. Blood samples were taken at various intervals and analyzed for aspirin content. The results of these tests are tabulated in the Table II below and graphically illustrated in FIG. 1.

From these test results it can be seen that a [0 grain timed-release aspirin tablet prepared in accordance with this invention provides a relatively constant, low blood level for up to 48 hours, as contrasted to the commercially available timed-release tablet which produces an initially high blood level content with a rapidly decreasing content. Also, it can be seen that a doublelayered 1O grain aspirin tablet, including a layer of standard aspirin. prepared in accordance with this invention, produces a more rapid release of aspirin but at a lower initial peak and the blood level decreases more gradually than that provided by the commercially available timed-release aspirin tablet. Therefore, larger initial doses can betaken of either a purely timed-release aspirin tablet or a double-layer tablet prepared in accordance with this invention to obtain a more constant pain relief for a longer period, without an initially high blood level peak resulting in potential toxicity and/or .upon reading the above detailed description, various other harmful side effects.

EXAMPLE v An in vivo test was conducted to evaluate the biological availability of an aspirin tablet prepared in accordance with this invention. Two double-layered l0 grain aspirin tablets prepared in accordance with the procedure outlined in Example [I were initially ingested by the same man as described in Example IV and 12 hours after the taking of the first dose a single double-layered l0 grain tablet prepared in the same manner was ingested. Blood samples were taken at various intervals and analyzed for aspirin content. The results of this test are tabulated in Table III below and graphically illustrated in FIG. 2.

From these test results, it can be seen that a substantially constant blood level existed for a period spanning from 8 hours after the initial dosage to 24 hours after the initial dosage when a second dosage was taken 12 hours after the initial dosage. The layer of standard aspirin ordinarily dissolves in the stomach within a matter of minutes and is reflected in the blood level. Therefore, it is believed that the lower level blood content of the particular patient tested during the first 8 hours following the initial dosage was caused by specific physiological factors of the patient at the time of initial ingestion and the data is not representative of the effectiveness of the aspirin during this period. This is borne out by the test described in Example IV where the same man ingested a double-layered tablet and there was a reflection of aspirin content in the blood within a relatively short time. The important effect shown by this test is the maintenance of a substantially constant blood level content for a long period of time, (i.e., up to 24 hours or more) without a significant peak in the blood level upon the ingestion of a second dosage. This I means that long term constant pain relief can be obtained by taking successive dosages at prescribed intervals without the danger of blood level peaks where toxicity or harmful side effects might occur.

As will be readily apparent to those skilled in the art modifications can be made thereto without departing from the spirit and scope of the invention.

We claim:

1. In a method for making an aspirin tablet including the steps of mixing uncoated particles of standard 80 mesh USP aspirin with a sufficient amount of a nonaqueous solution, containing about to about l8 weight cellulose acetate phthalate, a suitable amount of a pharmaceutically acceptable plasticizer to permit granules formed from said particles to be pressed into tablets without a tabletting excipient, and a parmaceutically acceptable solvent, to coat and impregnate each of the particles with said solution, forming the resulting mixture into discrete plasticized granules larger than said particles, drying said plasticized granules to remove substantially all the solvent therefrom, reducing said dried plasticized granules to a size whereby they can pass through a mesh screen and homogeneously mixing said reduced plasticized granules, the improvement consisting essentially of the steps of pressing said reduced plasticized granules without any tabletting cxcipients into dosage-size tablets to provide an aspirin tablet having timed-release characteristics.

2. A method according to claim 1 wherein said solvent is selected from the group consisting of acetone, methyl ethyl ketone, methanol, ethanol, isopropanol, methylene chloride, ethylene dichloride, chloroform and mixtures thereof.

3. A method according to claim 2 wherein said plasticizer is diethylphthalate.

a. A method according to claim 3 wherein the amount of said diethylphthalate in said solution is about 3 weight 5. A method according to claim 1 wherein the amount of cellulose acetate phthalate contained by each of said granules is about 0.5 to about 5.0% by weight, based on the total weight of the coated granule.

6. A method according to claim 1 wherein the amount of cellulose acetate phthalate in said solution is about 15 weight 7. In a method for making an aspirin tablet including the steps of mixing uncoated particles of standard mesh USP aspirin with a sufficient amount of a nonaqueous solution, containing about 15 weight% cellulose acetate phthalate, about 3 weight%. diethylphthalate and a pharmaceutically acceptable solvent selected from the group consisting of acetone, methyl ethyl ketone, methanol, ethanol, isopropanol, methylene chlo ride, ethylene dichloride, chloroform, and mixtures thereof, to coat and impregnate each of said particles with said solution, forming the resultant mixture into discrete plasticized granules larger than said particles, drying said plasticized granules to remove substantially all the solvent therefrom, reducing said dried plasticized granules to a size whereby they can pass through a 20 mesh screen and homogeneously mixing said reduced plasticized granules, the improvement consisting essentially of the steps of pressing said reduced plasticized granules without any tabletting cxcipients into dosage-size tablets to produce an aspirin tablet having timed-release characteristics.

Claims (7)

1. IN A METHOD FOR MAKING AN ASPIRIN TABLET INCLUDING THE STEP OF MIXING UNCOATED PARTICLES OF STANDARD 80 MESH UPS ASPIRIN WITH A SUFFICIENT AMOUNT OF A NON-AQUEOUS SOLUTION, CONTAINING ABOUT 5 TO ABOUT 18 WEIGHT % CELLULOSE ACETATE PHTHALATE, A SUITABLE AMOUNT OF A PHARMACEUTICALLY ACCEPTABLE PLASTICIZER TO PERMIT GRANULES FORMED FROM SAID PARTICLES TO BE PRESSED INTO TABLETS WITHOUT A TABLETING EXCIPIENT, AND A PARMACEUTICALLY ACCEPTABLE SOLVENT, TO COAT AND IMPREGNATE EACH OF THE PARTICLES WITH SAID SOLUTION, FORMING THE RESULTING MIXTURE INTO DISCRETE PLASTICIZED GRANULES LARGER THAN SAID PARTICLES, DRYING SAID PLASTICIZED GRANULES TO REMOVE SUBSTANTIALLY ALL THE SOLVENT THEREFROM, REDUCING SAID DRIED PLASTICIZED GRANULES TO A SIZE WHEREBY THEY CAN PASS THROUGH A 20 MESH SCREEN AND HOMOGENEOUSLY MIXING SAID REDUCED PLASTICIZED GRANULES, THE IMPROVEMENT CONSISTING ESSENTIALLY OF THE STEPS OF PRESSING SAID REDUCED PLASTICIZED GRANULES WITHOUT ANY TABLETING EXCIPIENTS INTO DOSAGE-SIZE TABLETS TO PROVIDE AN ASPIRIN TABLET HAVING TIMED-RELEASE CHARACTERISTICS.
2. A method according to claim 1 wherein said solvent is selected from the group consisting of acetone, methyl ethyl ketone, methanol, ethanol, isopropanol, methylene chloride, ethylene dichloride, chloroform and mixtures thereof.
3. A method according to claim 2 wherein said plasticizer is diethylphthalate.
4. A method according to claim 3 wherein the amount of said diethylphthalate in said solution is about 3 weight%.
5. A method according to claim 1 wherein the amount of cellulose acetate phthalate contained by each of said granules is about 0.5 to about 5.0% by weight, based on the total weight of the coated granule.
6. A method according to claim 1 wherein the amount of cellulose acetate phthalate in said solution is about 15 weight%.
7. In a method for making an aspirin tablet including the steps of mixing uncoated particles of standard 80 mesh USP aspirin with a sufficient amount of a non-aqueous solution, containing about 15 weight% cellulose acetate phthalate, about 3 weight%. diethylphthalate and a pharmaceutically acceptable solvent selected from the group consisting of acetone, methyl ethyl ketone, methanol, ethanol, isopropanol, methylene chloride, ethylene dichloride, chloroform, and mixtures thereof, to coat and impregnate each of said particles with said solution, forming the resultant mixture into discrete plasticized granules larger than said particles, drying said plasticized granules to remove substantially all the solvent therefrom, reducing said dried plasticized granules to a size whereby they can pass through a 20 mesh screen and homogeneously mixing said reduced plasticized granules, the improvement consisting essentially of the steps of pressing said reduced plasticized granules without any tabletting excipients into dosage-size tablets to produce an aspirin tablet having timed-release characteristics.
US3906086A 1971-07-19 1974-01-22 Timed-release aspirin Expired - Lifetime US3906086A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US16373971 true 1971-07-19 1971-07-19
US3906086A US3906086A (en) 1971-07-19 1974-01-22 Timed-release aspirin

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3906086A US3906086A (en) 1971-07-19 1974-01-22 Timed-release aspirin

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US16373971 Continuation 1971-07-19 1971-07-19

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US05590095 Division US4025613A (en) 1971-07-19 1975-06-25 Timed-release aspirin

Publications (1)

Publication Number Publication Date
US3906086A true US3906086A (en) 1975-09-16

Family

ID=26859904

Family Applications (1)

Application Number Title Priority Date Filing Date
US3906086A Expired - Lifetime US3906086A (en) 1971-07-19 1974-01-22 Timed-release aspirin

Country Status (1)

Country Link
US (1) US3906086A (en)

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4101651A (en) * 1975-09-29 1978-07-18 Meiji Seika Kaisha, Ltd. Process for preparing preparations for oral administration
FR2473308A1 (en) * 1980-01-11 1981-07-17 Boots Co Ltd pharmaceutical composition has effect prolongs and process for its preparation
US4308251A (en) * 1980-01-11 1981-12-29 Boots Pharmaceuticals, Inc. Controlled release formulations of orally-active medicaments
EP0129382A2 (en) * 1983-06-15 1984-12-27 SHIONOGI & CO., LTD. Long-acting formulation of cefaclor and its preparation
US4507276A (en) * 1982-08-20 1985-03-26 Bristol-Myers Company Analgesic capsule
US4643894A (en) * 1984-07-24 1987-02-17 Colorcon, Inc. Maltodextrin coating
US4704284A (en) * 1982-08-12 1987-11-03 Pfizer Inc. Long-acting matrix tablet formulations
US4720387A (en) * 1983-06-22 1988-01-19 Shionogi & Co., Ltd. Sustained-release preparation of pinacidil
EP0255725A2 (en) * 1986-08-06 1988-02-10 Eisai Co., Ltd. Sustained-release multi-granule tablet
US4786506A (en) * 1986-03-11 1988-11-22 Istituto Gentili S.P.A. Method for the preparation of granulates suited for the production of sustained release coated tablets for oral use
US4863741A (en) * 1985-03-25 1989-09-05 Abbott Laboratories Tablet composition for drug combinations
US4867984A (en) * 1984-11-06 1989-09-19 Nagin K. Patel Drug in bead form and process for preparing same
US4874614A (en) * 1985-03-25 1989-10-17 Abbott Laboratories Pharmaceutical tableting method
US4880791A (en) * 1984-07-21 1989-11-14 Hoechst Aktiengesellschaft Combination product composed of xanthine derivatives and O-acetylsalicylic acid or its pharmacologically tolerated salts, and its use
US4960765A (en) * 1980-03-20 1990-10-02 Farmaceutisk Laboratorium Ferring A/S Pharmaceutical composition and method for the treatment of colitis ulcerosa and Crohn's disease by oral administration
US4980173A (en) * 1980-03-20 1990-12-25 Farmaceutisk Laboratorium Ferring A/S Pharmaceutical composition and method for the treatment of colitis ulcerosa and Crohn's disease by oral administration
EP0413120A2 (en) * 1989-08-16 1991-02-20 Sterling Winthrop Inc. Aspirin granules with gastroprotectant coating
US5470581A (en) * 1990-04-04 1995-11-28 Berwind Pharmaceutical Services, Inc. Aqueous maltodextrin and cellulosic polymer film coatings
US6432448B1 (en) 1999-02-08 2002-08-13 Fmc Corporation Edible coating composition
US6500462B1 (en) 1999-10-29 2002-12-31 Fmc Corporation Edible MCC/PGA coating composition
US6699315B2 (en) 2000-11-28 2004-03-02 Fmc Corporation Edible PGA coating composition
US6723342B1 (en) 1999-02-08 2004-04-20 Fmc Corporation Edible coating composition
US20050171119A1 (en) * 2002-01-09 2005-08-04 Ucb, S.A. Pharmaceutical formulations with modified release
US6932861B2 (en) 2000-11-28 2005-08-23 Fmc Corporation Edible PGA coating composition
US20170112857A1 (en) * 2015-10-27 2017-04-27 New Haven Pharmaceuticals, Inc. Extended Release Aspirin

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2196768A (en) * 1938-03-11 1940-04-09 Eastman Kodak Co Enteric coating
US2953497A (en) * 1953-06-03 1960-09-20 Howard A Press Therapeutic tablets
US3112220A (en) * 1960-02-26 1963-11-26 Abbott Lab Method and apparatus for coating particles
US3247066A (en) * 1962-09-12 1966-04-19 Parke Davis & Co Controlled release dosage form containing water-swellable beadlet
US3325365A (en) * 1963-04-02 1967-06-13 Ciba Geigy Corp Enteric composition for tablet compression coating
US3400185A (en) * 1965-04-08 1968-09-03 Bristol Myers Co Agglomeration of smaller pharmaceutical particles into larger microspherules and enteic-coating thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2196768A (en) * 1938-03-11 1940-04-09 Eastman Kodak Co Enteric coating
US2953497A (en) * 1953-06-03 1960-09-20 Howard A Press Therapeutic tablets
US3112220A (en) * 1960-02-26 1963-11-26 Abbott Lab Method and apparatus for coating particles
US3247066A (en) * 1962-09-12 1966-04-19 Parke Davis & Co Controlled release dosage form containing water-swellable beadlet
US3325365A (en) * 1963-04-02 1967-06-13 Ciba Geigy Corp Enteric composition for tablet compression coating
US3400185A (en) * 1965-04-08 1968-09-03 Bristol Myers Co Agglomeration of smaller pharmaceutical particles into larger microspherules and enteic-coating thereof

Cited By (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4101651A (en) * 1975-09-29 1978-07-18 Meiji Seika Kaisha, Ltd. Process for preparing preparations for oral administration
FR2473308A1 (en) * 1980-01-11 1981-07-17 Boots Co Ltd pharmaceutical composition has effect prolongs and process for its preparation
DE3100191A1 (en) * 1980-01-11 1981-12-10 Boots Co Ltd Pharmaceutical preparation and process for its preparation
US4308251A (en) * 1980-01-11 1981-12-29 Boots Pharmaceuticals, Inc. Controlled release formulations of orally-active medicaments
US5041431A (en) * 1980-03-20 1991-08-20 Farmaceutisk Laboratorium Ferring A/S Pharmaceutical composition and method for the treatment of colitis ulcerosa and Crohn's disease by oral administration
US5013727A (en) * 1980-03-20 1991-05-07 Farmaceutisk Laboratorium Ferring A/S Pharmaceutical composition and method for the treatment of colitis ulcerosa and Crohn's disease by oral administration
US4980173A (en) * 1980-03-20 1990-12-25 Farmaceutisk Laboratorium Ferring A/S Pharmaceutical composition and method for the treatment of colitis ulcerosa and Crohn's disease by oral administration
US4960765A (en) * 1980-03-20 1990-10-02 Farmaceutisk Laboratorium Ferring A/S Pharmaceutical composition and method for the treatment of colitis ulcerosa and Crohn's disease by oral administration
US4704284A (en) * 1982-08-12 1987-11-03 Pfizer Inc. Long-acting matrix tablet formulations
US4507276A (en) * 1982-08-20 1985-03-26 Bristol-Myers Company Analgesic capsule
EP0129382A3 (en) * 1983-06-15 1986-07-09 Shionogi & Co., Ltd. Long-acting formulation of cefaclor and its preparation
EP0129382A2 (en) * 1983-06-15 1984-12-27 SHIONOGI & CO., LTD. Long-acting formulation of cefaclor and its preparation
US4720387A (en) * 1983-06-22 1988-01-19 Shionogi & Co., Ltd. Sustained-release preparation of pinacidil
US4880791A (en) * 1984-07-21 1989-11-14 Hoechst Aktiengesellschaft Combination product composed of xanthine derivatives and O-acetylsalicylic acid or its pharmacologically tolerated salts, and its use
US4643894A (en) * 1984-07-24 1987-02-17 Colorcon, Inc. Maltodextrin coating
US4867984A (en) * 1984-11-06 1989-09-19 Nagin K. Patel Drug in bead form and process for preparing same
US4863741A (en) * 1985-03-25 1989-09-05 Abbott Laboratories Tablet composition for drug combinations
US4874614A (en) * 1985-03-25 1989-10-17 Abbott Laboratories Pharmaceutical tableting method
US4786506A (en) * 1986-03-11 1988-11-22 Istituto Gentili S.P.A. Method for the preparation of granulates suited for the production of sustained release coated tablets for oral use
EP0255725A3 (en) * 1986-08-06 1991-01-30 Eisai Co., Ltd. Sustained-release multi-granule tablet
EP0255725A2 (en) * 1986-08-06 1988-02-10 Eisai Co., Ltd. Sustained-release multi-granule tablet
EP0413120A2 (en) * 1989-08-16 1991-02-20 Sterling Winthrop Inc. Aspirin granules with gastroprotectant coating
EP0413120A3 (en) * 1989-08-16 1992-02-26 Sterling Drug Inc. Aspirin granules with gastroprotectant coating
US5470581A (en) * 1990-04-04 1995-11-28 Berwind Pharmaceutical Services, Inc. Aqueous maltodextrin and cellulosic polymer film coatings
US6432448B1 (en) 1999-02-08 2002-08-13 Fmc Corporation Edible coating composition
US6723342B1 (en) 1999-02-08 2004-04-20 Fmc Corporation Edible coating composition
US6500462B1 (en) 1999-10-29 2002-12-31 Fmc Corporation Edible MCC/PGA coating composition
US6699315B2 (en) 2000-11-28 2004-03-02 Fmc Corporation Edible PGA coating composition
US6932861B2 (en) 2000-11-28 2005-08-23 Fmc Corporation Edible PGA coating composition
US20050171119A1 (en) * 2002-01-09 2005-08-04 Ucb, S.A. Pharmaceutical formulations with modified release
US20170112857A1 (en) * 2015-10-27 2017-04-27 New Haven Pharmaceuticals, Inc. Extended Release Aspirin
WO2017184488A1 (en) * 2015-10-27 2017-10-26 Espero Pharmaceuticals Inc. Extended release aspirin

Similar Documents

Publication Publication Date Title
US3431338A (en) Coated dosage form adapted to oral emetine or dehydroemetine therapy
US3670065A (en) Process for producing dosage units of a type resembling tablets
US3146169A (en) Pharmaceutical formulations and their manufacture
US3184386A (en) Prolonged action medicinal tablets
US5849327A (en) Delivery of drugs to the lower gastrointestinal tract
US5093200A (en) Multilayer sustained release granule
US5529790A (en) Delayed, sustained-release diltiazem pharmaceutical preparation
US3806603A (en) Pharmaceutical carriers of plasticized dried milled particles of hydrated cooked rice endosperm
US5004613A (en) Oral sustained release pharmaceutical formulation and process
US5505962A (en) Controlled release pharmaceutical formulation
US5188840A (en) Slow-release pharmaceutical agent
US3976764A (en) Solid therapeutic preparation remaining in stomach
US5529783A (en) Rotor granulation and coating of acetaminophen, pseudoephedrine, chlorpheniramine, and, optionally dextromethorphan
US3922339A (en) Sustained release medicant
US4983398A (en) Sustained release drug dosage forms containing hydroxypropylmethylcellulose and alkali metal carboxylates
US6602521B1 (en) Multiplex drug delivery system suitable for oral administration
US6372254B1 (en) Press coated, pulsatile drug delivery system suitable for oral administration
US3074852A (en) Pharmaceuticals with delayed release
US3279998A (en) Method of preparing sustained release tablets
Fukuda et al. Floating hot-melt extruded tablets for gastroretentive controlled drug release system
EP0108218A2 (en) Constant release rate solid oral dosage formulation of pharmaceutical compounds having a high degree of water solubility
US6682759B2 (en) Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
US2793979A (en) Method of making a sustained release pharmaceutical tablet and product of the method
US20060057207A1 (en) Fast-disintegrating dosage forms of 5,8,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaene
US20090175937A1 (en) Misuse Preventative, Controlled Release Formulation

Legal Events

Date Code Title Description
AS Assignment

Owner name: VEREX LABORATORIES, INC. 5241 SOUTH QUEBEC ST., EN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNORS:D ORAZIO, SANDRA J.;GUY, MICHAEL G.;STERN, JAMES F. INDIVIDUALLY;AND OTHERS;REEL/FRAME:004014/0233;SIGNING DATES FROM 19820610 TO 19820630

AS Assignment

Owner name: HITACHI, LTD., 5-1, 1-CHOME, MARUNOUCHI, CHIYODA-K

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNORS:KONISHI, NOBUTAKE;NAITO, MASAYOSHI;YATSUO, TSUTOMU;AND OTHERS;REEL/FRAME:004114/0594

Effective date: 19800702

Owner name: VEREX LABORATORIES, INC.; 5241 SOUTH QUEBEC ST., E

Free format text: ASSIGNS AS OF SEPTEMBER 1, 1981 THE ENTIRE INTEREST;ASSIGNORS:STERN, JAMES F. (AND);STERN, JOHN M., CO-PERSONAL REPRESENTATIVES OF ROBERT M. STERN;D ORAZIO, SANDRA .;AND OTHERS;REEL/FRAME:004121/0986;SIGNING DATES FROM 19830208 TO 19830216

AS Assignment

Owner name: BOOTS PHARMACEUTICALS, INC., 6540 LINE AVE., SHREV

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNOR:VEREX LABORATORIES, INC.;REEL/FRAME:004318/0515

Effective date: 19840919